DNTH · NASDAQ · STOCK
Dianthus Therapeutics, Inc.
$108.40
52W $19.00 – $114.55
54/100
$6.07B
-834.5
0.08
Is DNTH Bullish or Bearish?
Mixed.
Innellis AI committee rates Dianthus Therapeutics, Inc. (DNTH) Watch with a composite score of 54/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +5.50 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.50 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -60.8% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 1.86 means this name should amplify a favorable market regime — Macro
Bear Case
- ROE of only -22.5% -- cheap may mean cheap for a reason — Value
- Revenue declining -60.8% YoY -- this is not a growth story right now — Growth
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 17.0% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
54/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 87%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -22.5% -- cheap may mean cheap for a reason
Growth Analyst
bearish
15
/ 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -60.8% YoY -- this is not a growth story right now
Technical Analyst
neutral
57
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 17.0% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 6 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
52.5
Neutral
MACD Histogram
-0.175
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Lh Ll
Bollinger %B
0.65
Inside Bands
Price vs Moving Averages
EMA 9
$108.75
Below
EMA 21
$105.39
Above
EMA 50
$98.54
Above
EMA 200
$74.04
Above
Fundamental Analysis
Valuation
48
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-834.5×
P/B Ratio
5.19×
PEG Ratio
—
Dividend Yield
0.00%
52W High
$114.55
52W Low
$19.00
Quality & Growth
ROE
-3290.2%
ROA
-3057.6%
Gross Margin
9600.8%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -834.5 (inexpensive relative to a 15-40x range); Price-to-book of 5.2x; PEG ratio of 137.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -32.9%; Return on assets of -30.6%; Net margin of -1570.9%; Gross margin of 96.0%; Current ratio of 26.10 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-2.78); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full DNTH Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →